X4 Pharmaceuticals (XFOR) PT Lowered to $8 at Oppenheimer on Higher Q1 Loss, but Stays "Bullish on XFOR Ahead of Pivotal WHIM Data"
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell lowered the price target on X4 Pharmaceuticals (NASDAQ: XFOR) to $8.00 (from $13.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
